NDA accepted by FDA
Global pharmaceutical company Bristol Myers Squibb (BMS) has announced that its New Drug Application (NDA) has been accepted by the US Food and Drug Administration (FDA) for its ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) treatment repotrectinib.
Repotrectinib (TPX-0005, BMS-986472) is a next-generation, potentially best-in-class tyrosine kinase inhibitor (TKI), designed to improve the durability of response with favourable properties for human brain penetration to enhance intracranial activity.
The post Bristol Myers Squibb’s NDA accepted by FDA appeared first on Pharmafile.
